Pomerantz Law Firm Investigates Potential Securities Fraud at Tyra Biosciences
The law firm of Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Tyra Biosciences, Inc. (NASDAQ: TYRA) and certain officers or directors on behalf of investors. The investigation follows the company's announcement in early September 2026 about initial results from its Phase 2 clinical trial for oral dabogratinib in treating bladder cancer. The data showed a favorable safety profile but also revealed that 14% and 9% of participants experienced Grade 3 adverse events at two different dosage levels. This news led to an immediate drop in Tyra's stock price, falling $4.72 per share (or 17.66%) on September 9, 2026. Pomerantz LLP is a well-known firm specializing in corporate and securities litigation with offices across the U.S., London, Paris, and Tel Aviv.
Tickers: $TYRA
Topics: clinical_trials legal pharmaceuticals